Showing results (151-160 of 200) with videos related to
Sort By:
Pageof 20
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 10, 2026
FRUQUITAS trial: Study design of an ENGIC intergroup randomized phase III of trifluridine/tipiracil +/- fruquintinib in pre-treated metastatic gastro-oesophageal adenocarcinomaDavid Tougeron, Fernando Rivera, Tania Fleitas Kanonnikoff, et al.European Journal of Cancer (Oxford, England : 1990)|June 21, 2017
First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)Alfredo Carrato, Albert Abad, Bartomeu Massuti, et al.Targeted Oncology|December 16, 2017
Correction to: A Phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer PatientsMaria Alsina, Fernando Rivera, Francisco Javier Ramos, et al.Plos One|November 24, 2012
Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative studyEduardo Díaz-Rubio, Auxiliadora Gómez-España, Bartomeu Massutí, et al.Cancers|May 28, 2022
Gold Glyconanoparticles Combined with 91-99 Peptide of the Bacterial Toxin, Listeriolysin O, Are Efficient Immunotherapies in Experimental Bladder TumorsHector Terán-Navarro, Andrea Zeoli, David Salines-Cuevas, et al.The Oncologist|March 10, 2017
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal CancerRocío García-Carbonero, Eric van Cutsem, Fernando Rivera, et al.Targeted Oncology|November 13, 2017
A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer PatientsMaria Alsina, Fernando Rivera, Francisco Javier Ramos, et al.Oncoimmunology|February 5, 2019
Pre-clinical development of Listeria-based nanovaccines as immunotherapies for solid tumours: insights from melanomaHector Terán-Navarro, Ricardo Calderon-Gonzalez, David Salcines-Cuevas, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2007
Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancerAimery de Gramont, Marc Buyse, Jose Cortinas Abrahantes, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 26, 2011
Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinomaCarlos Gómez-Martín, Angel Concha, José María Corominas, et al.Pageof 20